Фиксированная комбинация периндоприлааргинина с амлодипином как новый шаг в совершенствовании антигипертензивнойтерапии
Фиксированная комбинация периндоприлааргинина с амлодипином как новый шаг в совершенствовании антигипертензивнойтерапии
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Poulter N, Sever P. Anglo-Scandinavian Cardiac Outcomes Trial. History, results and implications for the management of high blood pressure. Birmingham: Sherborne Gibbs Ltd; 200 05.
2. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group JAMA 2002; 288:2981–97.
3. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients Kenneth Jamerson, M.D., Michael A. Weber, M.D., George L. Bakris, M.D., Björn Dahlöf, M.D., Bertram Pitt, M.D., Victor Shi, M.D., Allen Hester, Ph.D., Jitendra Gupte, M.S., Marjorie Gatlin, M.D. and Eric J. Velazquez, M.D. for the ACCOMPLISH Trial nvestigators N Engl J Med 2008; 359:2417–28.
4. Bahl VK, Jadhav UM, Thacker НР. Management of Hypertension with the Fixed Combination of Perindopril and Amlodipine in Daily Clinical Practice Results from the STRONG Prospective, Observational, Multicenter Study. Am J Cardiovasc Drugs 2009; 9 (3): 135–42.
5. Julius S, Kjeldsen SE, Weber M, for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022–31.
6. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo controlled, multicenter trail (the EUROPA study). Lancet 2003; 362: 782–8.
7. Agabiti-Rosei Е, Mancia G, O'Rourke M et al. Central Blood Pressure Measurements and Antihypertensive Therapy. A Consensus Document Hypertension. 2007; 50: 154–60.
8. Roman MJ et. al. Central Pressure More Strongly Relates to Vascular Disease and Outcome Than Does Brachial Pressure; The Strong Heart Study. Hypertension 2007; 50: 197–203.
9. Agabiti-Rosei E, Rizzoni D. Regression of small resistance artery structural alterations in hypertension by appropriate antihypertensive treatment. Curr Hypertens Rep 2010; 12 (2): 80–5.
10. Ceconi C, Fox KM, Remme JM et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
11. Rothwell P, Howard SC, Dolan E et al. Effects of _ blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet 2010; 375: 895–905.
12. Dolan E, Stanton AV, Thom S et al. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens 2009; 27: 876–85.
13. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomised controlled trial. JAMA 2003; 290: 2805–16.
2. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group JAMA 2002; 288:2981–97.
3. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients Kenneth Jamerson, M.D., Michael A. Weber, M.D., George L. Bakris, M.D., Björn Dahlöf, M.D., Bertram Pitt, M.D., Victor Shi, M.D., Allen Hester, Ph.D., Jitendra Gupte, M.S., Marjorie Gatlin, M.D. and Eric J. Velazquez, M.D. for the ACCOMPLISH Trial nvestigators N Engl J Med 2008; 359:2417–28.
4. Bahl VK, Jadhav UM, Thacker НР. Management of Hypertension with the Fixed Combination of Perindopril and Amlodipine in Daily Clinical Practice Results from the STRONG Prospective, Observational, Multicenter Study. Am J Cardiovasc Drugs 2009; 9 (3): 135–42.
5. Julius S, Kjeldsen SE, Weber M, for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022–31.
6. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo controlled, multicenter trail (the EUROPA study). Lancet 2003; 362: 782–8.
7. Agabiti-Rosei Е, Mancia G, O'Rourke M et al. Central Blood Pressure Measurements and Antihypertensive Therapy. A Consensus Document Hypertension. 2007; 50: 154–60.
8. Roman MJ et. al. Central Pressure More Strongly Relates to Vascular Disease and Outcome Than Does Brachial Pressure; The Strong Heart Study. Hypertension 2007; 50: 197–203.
9. Agabiti-Rosei E, Rizzoni D. Regression of small resistance artery structural alterations in hypertension by appropriate antihypertensive treatment. Curr Hypertens Rep 2010; 12 (2): 80–5.
10. Ceconi C, Fox KM, Remme JM et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
11. Rothwell P, Howard SC, Dolan E et al. Effects of _ blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet 2010; 375: 895–905.
12. Dolan E, Stanton AV, Thom S et al. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients – an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens 2009; 27: 876–85.
13. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomised controlled trial. JAMA 2003; 290: 2805–16.
Авторы
С.А.Бойцов
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.